Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Newcastle disease + infectious bronchitis + H9 avian influenza trivalent inactivated vaccine (Youbang Pharmaceutical)
- Development stage
- Unknown
- Lead developer
- Jinyu Youbang Biotechnology
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
This trivalent inactivated veterinary vaccine is developed by Youbang Pharmaceutical (Yangzhou Youbang Biological Pharmaceutical Co., Ltd.) for the active immunization of poultry, specifically chickens. The vaccine is designed to provide simultaneous protection against three significant avian pathogens: Newcastle disease virus (NDV), Infectious bronchitis virus (IBV), and the H9 subtype of Avian influenza virus (AIV). It is produced by inactivating the respective viral strains and formulating them into a single injectable product, typically utilizing an oil-in-water emulsion adjuvant to enhance the immune response. The vaccine is primarily used in commercial poultry operations to prevent respiratory distress, significant drops in egg production, and mortality associated with these infections.
- Other names
- 鸡新城疫、传染性支气管炎、禽流感(H9亚型)三联灭活疫苗ND-IB-H9 trivalent inactivated vaccineND-IB-H-9 trivalent inactivated vaccineND-IB-H 9 trivalent inactivated vaccineNewcastle disease virus (NDV) + Infectious bronchitis virus (IBV) + Avian influenza virus (H9 subtype) inactivated vaccine
Beyond the preview
Go deeper on Newcastle disease + infectious bronchitis + H9 avian influenza trivalent inactivated vaccine (Youbang Pharmaceutical).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Newcastle disease + infectious bronchitis + H9 avian influenza trivalent inactivated vaccine (Youbang Pharmaceutical).